Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CT 03 programme - Captor Therapeutics

Next Previous
X
Search
Drug Profile

CT 03 programme - Captor Therapeutics

Alternative Names: CT-03; CT-03 degraders; CT-03 project

Latest Information Update: 17 Dec 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Captor Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action MCL1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Haematological malignancies; Solid tumours

Most Recent Events

  • 26 Oct 2022 Pharmacodynamics data from preclinical trial in Haematological malignancies presented at the 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR-2022)
  • 25 Jan 2022 CT 03 is available for licensing as of 13 Jan 2022. http://www.captortherapeutics.com/our-approach
  • 20 Jan 2022 Captor Therapeutics plans to submit IND application for CT 03 degraders

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top